Metabolic Dysfunction-associated Steatotic Liver Disease in Romania: A Multidisciplinary Position Paper on Prevalence, Clinical Spectrum, Prevention, Screening and Management

J Gastrointestin Liver Dis. 2026 Aug 18. doi: 10.15403/jgld-7454. Online ahead of print.ABSTRACTBACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease globally and a rising cause of cirrhosis, hepatocellular carcinoma, liver

L Liliana-Simona Gheorghe

Strategies for preventing and reversing atrial cardiomyopathy (AtCM): current evidence, therapeutic targets, and future directions. A European Journal of Heart Failure expert consensus statement

Eur J Heart Fail. 2026 Aug 19:xuag268. doi: 10.1093/ejhf/xuag268. Online ahead of print.ABSTRACTAtrial cardiomyopathy (AtCM) encompasses all forms of electrical atrial dysfunction in combination with mechanical atrial dysfunction, atrial enlargement and/or excessive atrial fibrosis. A growing body o

R Rosita Zakeri

Hope for heart failure with preserved ejection fraction?

Sci Adv. 2026 Aug 21;12(34):eaek5991. doi: 10.1126/sciadv.aek5991. Epub 2026 Aug 19.ABSTRACTA common form of heart failure improves when cyclic guanosine monophosphate-dependent protein kinase is activated with a novel agent that promotes cysteine-42 oxidation.PMID:42616904 | DOI:10.1126/sciadv.aek5

R Robert M Blanton

Machine Learning-Based Risk Prediction of In-Hospital Mortality in Patients With Non-ST-Elevation Acute Coronary Syndrome at Various Stages of the Diagnostic Process: Observational Study

JMIR Med Inform. 2026 Aug 19;14:e89242. doi: 10.2196/89242.ABSTRACTBACKGROUND: Despite advances in understanding and treating non-ST-elevation acute coronary syndrome (NSTE-ACS), patients continue to experience high rates of adverse outcomes, particularly those with non-ST-segment elevation myocardi

V Vyacheslav V Ryabov

Correlates of physical activity behaviour in a population sample with increased cardiovascular risk and established cardiovascular disease: Cross-sectional analysis of data from the Paracelsus 10,000 prospective cohort study in Salzburg, Austria

PLoS One. 2026 Aug 19;21(8):e0356607. doi: 10.1371/journal.pone.0356607. eCollection 2026.ABSTRACTRegular physical activity (PA) remains challenging for many people with high cardiovascular risk and established cardiovascular disease (CVD). We aimed to study correlates of PA behaviour in a populatio

S Stefan T Kulnik

Peritoneal Dialysis in the Transplant Pathway: From Waitlist to Graft Failure

Kidney360. 2026 Aug 19. doi: 10.34067/KID.0000001376. Online ahead of print.ABSTRACTPeritoneal dialysis (PD) is recognized as a well-established and safe modality of replacement therapy for patients with end-stage kidney disease. Recently, its use has attracted growing interest as a bridge to kidney

C Carlo Alfieri

The Eye as a Window to Cardio-Kidney-Metabolic Disease

Clin J Am Soc Nephrol. 2026 Aug 19. doi: 10.2215/CJN.0000001224. Online ahead of print.ABSTRACTThe Cardiovascular-Kidney-Metabolic (CKM) syndrome reframes cardiovascular, kidney, and metabolic disease as an integrated continuum, yet its management relies on reactive laboratory markers with substanti

J Jung Tak Park

Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial

JAMA Cardiol. 2026 Aug 19. doi: 10.1001/jamacardio.2026.2992. Online ahead of print.ABSTRACTIMPORTANCE: Left atrial (LA) dysfunction may play an important role in the pathophysiology of transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and is driven by LA remodeling and amyloid infiltration.OB

K Karola S Jering